Tatsuyuki Chiyoda
ORCID: 0000-0002-8214-2242
· 7 papers in corpus
2025
ObjectiveMedroxyprogesterone acetate (MPA) is an effective fertility-preserving treatment for early endometrial cancer and atypical endometrial hyperplasia (AEH), and rarely leads to the development of extrauterine lesions (ELs). We aimed t…
2025
There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids and determin…
2025
BackgroundBorderline ovarian tumors (BOTs) differ from ovarian carcinomas in their clinical presentation and behavior, yet their molecular characteristics remain poorly understood. This study aims to address this gap by integrating whole-ex…
other
2022
正常卵管3例、子宮内膜症（卵巣子宮内膜症性嚢胞）3例、卵巣癌（高異型度漿液性癌3例、明細胞癌3例）について質量分析を用いた解析を行った。正常卵管は高異型度漿液性癌の、子宮内膜症は明細胞癌のそれぞれ発症母地である。まずノンターゲットの脂質解析を行った。CE18.2、CE18.1、CE20.4、CE20.3、CE22.6、CE20.5、CE22.4、CE16.1、CE22.5、CE20.2、CE18.3の発現が正常卵管に比して子宮内膜症および卵巣癌では高かった。高異型度漿液性癌に…
2020
Precision medicine based on cancer genomics is being applied in clinical practice. However, patients do not always derive benefits from genomic testing. Here, we performed targeted amplicon exome sequencing-based panel tests, including 160 …
2020
Uterine leiomyoma is one of the most common gynaecologic benign tumours, but its genetic basis remains largely unknown. Six previous GWAS identified 33 genetic factors in total. Here, we performed a two-staged GWAS using 13,746 cases and 70…
2020
The use of primary patient-derived organoids for drug sensitivity and resistance testing could play an important role in precision cancer medicine. We developed expandable ovarian cancer organoids in < 3 weeks; these organoids captured the …